EPIRUS Reports Fourth Quarter and Fiscal Year 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
EPIRUS Biopharmaceuticals (EPRS) PT Raised to $13 at Leerink Partners
March 25, 2015 6:19 AM EDTLeerink Partners analyst Jason Gerberry reiterated an Outperform rating and boosted his price target on EPIRUS Biopharmaceuticals (NASDAQ: EPRS) to $13.00 (from $10.00) saying the pipeline is on track and the company has a cash runway into 2016.
Gerberry commented, "This morning EPRS provided several... More
EPIRUS Biopharma (EPRS) Tops Q4 EPS by 19c
March 23, 2015 4:38 PM EDTEPIRUS Biopharma (NASDAQ: EPRS) reported Q4 EPS of ($0.80), $0.19 better than the analyst estimate of ($0.99).
For earnings history and earnings-related data on EPIRUS Biopharma (EPRS) click here.
... More